EUIPO trademark

UPTEMPO

RegisteredEUIPOWord markClass 1Class 5Class 40Class 42

"UPTEMPO" is a word mark owned by Catalent Pharma Solutions, Inc., filed at the EUIPO on May 12, 2023. It is registered and covers classes 1, 5, 40 and 42.

View Catalent Pharma Solutions, Inc. portfolioGet this data via the API
Official EUIPO record
UPTEMPO
Word mark as filed with the EUIPO
Status
Registered
Since September 22, 2023
Filed
May 12, 2023
Registered
September 21, 2023
Expires
May 12, 2033
Application no.
018874525
Registration no.
018874525
Office
EUIPO
European Union Intellectual Property Office
Mark type
Word mark
4 classes
Ownership

Who owns UPTEMPO

The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.

Owner

Catalent Pharma Solutions, Inc.

141 trademarks in the portfolioView company

Representative

Gevers

Goods and services

What the mark covers

The products and services UPTEMPO is filed for, grouped by Nice class.

  • Cells and cell lines for scientific, laboratory or medical research; Reagents for scientific or medical research use; Biological and biochemical preparations, namely, plasmids, RNA and proteins for scientific, medical research, or research use; Cell culture reagents for scientific and research use; Stem cells for research or scientific purposes; Biological preparations for use in cell cultures other than for medical or veterinary use; Engineered proteins for use in scientific research and analysis relating to genetic diseases, gene therapy, and cell therapy; biochemicals and biologics, namely, engineered nucleic acids, viral vectors, non-viral vectors, gene therapy vectors, gene editing vectors, genetically modified cells, engineered proteins for multiplexed gene editing, mRNA and recombinant adeno-associated virus (AAV) vectors for delivery of therapeutic DNA or mRNA sequences to cells; biochemicals and biologics, namely antibody preparations, chimeric antigen receptor (CAR) T-cell preparations, T-cell preparations, tumor-infiltration lymphocyte (TIL) preparations, natural killer (NK) cell preparations, induced pluripotent stem cell (iPSC) preparations, mesenchymal stem cell (MSC) preparations; all of the aforementioned for use in scientific research and analysis

  • Cells and cell lines for medical or clinical use; Stem cells for medical or veterinary use; Engineered proteins for clinical use, medical use, clinical laboratory use and medical laboratory use relating to genetic diseases, gene therapy, and cell therapy; biochemicals and biologics, namely, engineered nucleic acids, viral vectors, non-viral vectors, gene therapy vectors, gene editing vectors, DNA plasmids, genetically modified cells, engineered proteins for multiplexed gene editing all for clinical use, medical use, clinical laboratory use, and medical laboratory use; biochemicals and biologics, namely mRNA and recombinant adeno-associated virus (AAV) vectors for delivery of therapeutic DNA or mRNA sequences to cells, antibody preparations, chimeric antigen receptor (CAR) T-cell preparations, T-cell preparations, tumor-infiltration lymphocyte (TIL) preparations, natural killer (NK) cell preparations, all for clinical use, medical use, clinical laboratory use, and medical laboratory use; biochemicals and biologics, namely, induced pluripotent stem cell (iPSC) preparations, mesenchymal stem cell (MSC) preparations, all for clinical use, medical use, clinical laboratory use, and medical laboratory use; Pharmaceutical preparations in the nature of viral systems, gene therapy systems, and nucleic acid delivery systems comprised of viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells used to deliver modified genetic material into other cells for medical purposes

  • Custom manufacture of cells and cell lines for use in viral vector production, and for diagnostic, medical and commercial applications in relation to cell and gene therapies

  • Pharmaceutical research and development; Gene therapy research; Cell therapy research; Scientific research

History

What has happened so far

Steps recorded by the EUIPO, newest first.

  1. Bulletin 2024/082 Section C.2.1
  2. Bulletin 2023/180 Section B.1
  3. Bulletin 2023/109 Section A.1
FAQ

About UPTEMPO

Who owns the trademark "UPTEMPO"?

The EUIPO trademark "UPTEMPO" (application 018874525) is owned by Catalent Pharma Solutions, Inc.

What is the status of "UPTEMPO"?

Its status at the EUIPO is: registered.

When was "UPTEMPO" registered?

It was registered on September 21, 2023 and is due to expire on May 12, 2033.

API

Get this data via the API

Everything on this page comes from the Signa API. Pull UPTEMPO and marks like it into your own product with one request.

  • GET/v1/trademarks/{id}

    The full record: owners, classes, dates and images

  • GET/v1/trademarks/{id}/events

    Every step in the office history

  • GET/v1/proceedings?trademark_id={id}

    Oppositions and cancellations against the mark

Get API keyView docs
GET /v1/trademarks/{id}
ID=tm_019d4562-32a0-77c3-9203-19fa14036316
curl https://api.signa.so/v1/trademarks/$ID \
  -H "Authorization: Bearer $SIGNA_API_KEY"
Response
{
  "id": "tm_019d4562-32a0-77c3-9203-19fa14036316",
  "object": "trademark",
  "mark_text": "UPTEMPO",
  "status": {
    "primary": "active",
    "stage": "registered"
  },
  "office_code": "EM",
  "application_number": "018874525",
  "filing_date": "2023-05-12",
  "nice_classes": [
    1,
    5,
    40,
    42
  ],
  "owners": [
    {
      "name": "Catalent Pharma Solutions, Inc.",
      "entity_id": "ent_019eb6fc-3d59-70de-b77a-e1780d3638e9"
    }
  ]
}